Vergoeding 2020-2024 voor ATC-subgroep S01LA : Oculaire antineovascularisatiemiddelen
- Raming voor de totale Zvw-populatie
| 2020 | 2021 | 2022 | 2023* | 2024* | |
|---|---|---|---|---|---|
| S01LA01 Verteporfine | 634.280 | 354.461 | 286.989 | 337.486 | 367.103 |
| S01LA04 Ranibizumab | 20.580.810 | 21.151.373 | 18.813.011 | 17.626.897 | 15.351.133 |
| S01LA05 Aflibercept | 72.250.190 | 87.618.452 | 95.120.623 | 110.456.081 | 115.062.590 |
| S01LA06 Brolucizumab | 31.243 | 295.971 | 473.345 | 529.517 | 356.302 |
| S01LA09 Faricimab | . | . | . | 1.021.834 | 7.282.704 |
| Totaal | 93.496.523 | 109.420.256 | 114.693.969 | 129.971.816 | 138.419.832 |